Please assess the completion status of the following clinical trial:

Trial Title: A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have SCD \[homozygous sickle cell (HbSS) or hemoglobin (HbS) Beta\^0 thalassemia\]~* Are participants with SCD who have had ≥2 episodes of vaso-occlusive crisis (VOC) in the past year~* Have a body weight ≥19 kilograms (kg) and are ≥2 and \<18 years of age, inclusive at the time of screening~* If participants are ≥2 and ≤16 years of age, must have had a transcranial Doppler within the last year~Exclusion Criteria:~* History of: transient ischemic attack (TIA)/ ischemic or hemorrhagic stroke, severe head trauma, intracranial hemorrhage, intracranial neoplasm, arteriovenous malformation, or aneurysm~* History of abnormal or conditional \[velocity in middle or anterior cerebral, or internal carotid artery ≥170 centimeter per second (cm/sec)\] transcranial Doppler within the last year~* History of, or are undergoing treatment with, chronic red blood cell (RBC) transfusion therapy~* Are at an increased risk for bleeding complications~* Are receiving chronic treatment with nonsteroidal anti-inflammatory drug (NSAID)s and cannot be switched to another analgesic

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Prasugrel (Type: EXPERIMENTAL): Participants will be titrated from initial daily dose of 0.08 milligram per kilogram (mg/kg) of orally administered prasugrel monotherapy at randomization to a dose that will achieve a P2Y12 reaction units (PRU) level of 231 to 136, as measured by VerifyNow instrument. This corresponds to a range of platelet inhibition of approximately 30% to 60%. The maximum possible dose allowed is 0.12 mg/kg daily, not to exceed 10 mg daily.
- Placebo (Type: PLACEBO_COMPARATOR): Participants in this treatment group will receive daily orally administered placebo and will follow visit schedule identical to that in the active treatment group.

Based on this trial design, predict the completion outcome and termination type (if applicable).